Cartilage repair remains one of the most formidable challenges in orthopedic regenerative medicine. Unlike bone or skin, cartilage possesses a limited intrinsic capacity for self-repair due to its avascular nature, low cellular density, and the relative inactivity of chondrocytes in the adult joint. Trauma, osteoarthritis, and degenerative diseases frequently lead to cartilage defects that, if left untreated, progress to joint pain, loss of function, and ultimately total joint replacement. Over the past decade, growth factor therapy has emerged as a powerful strategy to stimulate chondrogenesis, but delivering these bioactive proteins in a sustained, localized manner has proven difficult. Hydrogel-based delivery systems have risen to the forefront of cartilage tissue engineering because they can encapsulate growth factors, protect them from degradation, and release them over clinically relevant timeframes. This article provides an authoritative overview of hydrogel-based sustained release systems for cartilage repair, covering the fundamentals of hydrogel design, key growth factors, release mechanisms, current challenges, and future directions.

Understanding Hydrogels as Drug Delivery Vehicles

Hydrogels are three-dimensional networks of hydrophilic polymers that can absorb and retain large quantities of water—often 90% or more of their total weight. This high water content, coupled with their soft and elastic mechanical properties, makes them strikingly similar to native extracellular matrix (ECM). In the context of cartilage repair, hydrogels serve dual roles: they act as a structural scaffold that fills the defect site and provide a depot from which growth factors are released in a controlled manner. The polymer chains are crosslinked either physically (through ionic interactions, hydrogen bonds, or hydrophobic associations) or chemically (via covalent bonds) to form a stable network. The crosslinking density, polymer concentration, and chemical composition all influence the mesh size, degradation rate, and ultimately the release kinetics of encapsulated payloads.

Key advantages of hydrogels include their injectability (many formulations can be administered via minimally invasive arthroscopic procedures), their ability to be loaded with cells and bioactive molecules, and the ease with which their mechanical properties can be tuned to match those of native cartilage. For sustained growth factor release, hydrogels offer additional benefits: they protect proteins from enzymatic cleavage, reduce the frequency of administration (thus improving patient compliance), and minimize systemic side effects by localizing the therapy to the joint space. A growing body of literature supports the use of hydrogels for cartilage repair, with clinical translation already underway for certain formulations (reviewed in this 2023 article).

Growth Factors Central to Cartilage Regeneration

Growth factors are signaling proteins that orchestrate cellular behavior, including proliferation, differentiation, and matrix synthesis. In cartilage repair, several growth factors have shown particular promise:

  • Transforming Growth Factor-Beta (TGF-β): The most extensively studied growth factor for chondrogenesis. TGF-β superfamily members (TGF-β1, TGF-β2, TGF-β3) stimulate mesenchymal stem cells (MSCs) to differentiate into chondrocytes and promote the synthesis of collagen type II and aggrecan, the major ECM components of articular cartilage.
  • Bone Morphogenetic Proteins (BMPs): BMP-2, BMP-4, and BMP-7, also members of the TGF-β superfamily, are potent inducers of cartilage and bone formation. BMP-7 (also known as Osteogenic Protein-1) has been used in clinical trials for cartilage repair.
  • Insulin-like Growth Factor-1 (IGF-1): Promotes matrix synthesis and inhibits matrix degradation mediated by catabolic cytokines. It acts synergistically with other growth factors to enhance chondrogenic outcomes.
  • Fibroblast Growth Factor Family (FGF): FGF-2 (basic FGF) stimulates chondrocyte proliferation and has been shown to protect cartilage in osteoarthritis models, while FGF-18 (sprifermin) is currently in clinical development for its anabolic effects on cartilage.
  • Platelet-Derived Growth Factor (PDGF): Recruits MSCs and promotes their proliferation; often used in combination with other factors.

The challenge is that these proteins have short half-lives in vivo—on the order of minutes to hours—due to proteolysis, rapid clearance, and binding to ECM components. Therefore, a delivery system that can sequester the growth factor at the defect site and release it over weeks or months is essential for achieving therapeutic efficacy.

Hydrogel Types for Sustained Release in Cartilage Repair

A wide variety of hydrogel materials have been investigated for cartilage applications. They can be broadly classified into natural polymers, synthetic polymers, and hybrid systems. Each class presents distinct trade-offs between biocompatibility, mechanical strength, degradation behavior, and the ability to control release kinetics.

Natural Polymer Hydrogels

Natural hydrogels are derived from biological sources and are inherently biocompatible, often featuring intrinsic cell-adhesion motifs that support chondrocyte attachment and function. Common examples include:

  • Collagen: The major protein in native cartilage ECM. Collagen hydrogels (especially type I and type II) are widely used due to their bioactivity and ability to support chondrogenesis. Their degradation rate can be tuned by crosslinking density. However, they often lack mechanical strength for load-bearing applications.
  • Hyaluronic Acid (HA): A glycosaminoglycan naturally abundant in cartilage and synovial fluid. HA hydrogels can be chemically modified to form stable gels and are particularly attractive because they bind to CD44 receptors on chondrocytes, promoting cell signaling and matrix production. Viscosupplementation with HA is already used clinically for osteoarthritis, and HA-based hydrogels are now being developed for sustained growth factor delivery (recent review).
  • Alginate: A seaweed-derived polysaccharide that forms hydrogels in the presence of divalent cations like calcium. Alginate is biocompatible, injectable, and has been used to encapsulate growth factors and MSCs. Its main drawback is the lack of mammalian cell-adhesion sites, requiring chemical modification.
  • Chitosan: Derived from chitin, chitosan is cationic and can form polyelectrolyte complexes with negatively charged molecules. It is antimicrobial and can be blended with other polymers to improve mechanical properties.
  • Gelatin: Denatured collagen that retains cell-binding motifs (RGD sequences). Gelatin methacryloyl (GelMA) is a widely used photocrosslinkable derivative that allows precise spatial and temporal control of gelation.

Natural hydrogels typically degrade via enzymatic or hydrolytic mechanisms, which can be beneficial for full resorption and remodeling by host tissue. However, their mechanical weakness and batch-to-batch variability remain limitations.

Synthetic Polymer Hydrogels

Synthetic hydrogels offer superior control over mechanical properties, degradation rates, and chemical composition. They do not rely on animal-derived materials, reducing immunogenicity risks. Key examples include:

  • Polyethylene Glycol (PEG): The gold standard synthetic hydrogel. PEG is inert, hydrophilic, and can be functionalized with crosslinkable groups (e.g., PEG-diacrylate, PEG-maleimide) to form hydrogels with tunable stiffness and mesh size. Many strategies incorporate bioactive peptides (e.g., RGD, MMP-cleavable sequences) to impart cell responsiveness. PEG hydrogels have been used for sustained release of TGF-β, BMP-2, and IGF-1.
  • Polyvinyl Alcohol (PVA): Highly hydrophilic and easy to process. PVA hydrogels are physically crosslinked via freeze-thaw cycles, forming ice microcrystals that act as crosslinks. They exhibit high mechanical strength and can be used for load-bearing cartilage defects.
  • Poly(N-isopropylacrylamide) (PNIPAM): A thermoresponsive polymer that undergoes a phase transition at around 32°C, allowing sol-gel transition at body temperature—ideal for injectable delivery.
  • Poly(lactic-co-glycolic acid) (PLGA): Although typically used as microspheres rather than bulk hydrogels, PLGA can be combined with hydrophilic polymers to form composite hydrogels with tailorable degradation kinetics.

Synthetic hydrogels generally lack bioactivity unless modified, and their degradation products (e.g., lactic acid, glycolic acid) can create acidic microenvironments that may be detrimental to chondrocytes.

Hybrid and Composite Hydrogels

To harness the advantages of both natural and synthetic materials, many researchers have turned to hybrid systems. For example, PEG hydrogels can be grafted with collagen, HA, or RGD peptides to improve cell adhesion. Interpenetrating networks (IPNs) combine two independent polymer networks to enhance mechanical toughness. Another emerging approach is the incorporation of nanoparticles (e.g., mesoporous silica nanoparticles, hydroxyapatite nanoparticles) into the hydrogel matrix to provide an additional barrier for diffusion and to create a more sustained release profile. Such nanocomposite hydrogels are being actively studied for their ability to release multiple growth factors in a programmed sequence (recent example).

Strategies for Achieving Sustained Growth Factor Release

The release of growth factors from hydrogels can occur through several mechanisms, often operating in parallel: diffusion through the polymer network, swelling of the hydrogel (which increases mesh size), degradation (erosion) of the polymer chains, and specific affinity interactions between the growth factor and the matrix. Achieving sustained release typically requires slowing down diffusion and prolonging the residence time of the protein within the gel.

Physical Entrapment

The simplest approach is to dissolve the growth factor in the hydrogel precursor solution before crosslinking. The resulting polymer network physically traps the protein. Release then occurs via diffusion through the mesh. This method is straightforward but often results in a burst release as a substantial portion of the protein near the surface desorbs quickly. To mitigate burst release, one can increase crosslinking density (reducing mesh size) or use a hydrogel with a higher concentration of polymer. However, this can also hinder cell migration and matrix deposition.

Encapsulation in Micro- or Nanocarriers

A more refined strategy involves first encapsulating the growth factor within a secondary carrier, such as PLGA microspheres, liposomes, or chitosan nanoparticles, and then embedding these carriers within the hydrogel. The inner carrier provides an additional diffusion barrier and can be tailored to degrade slowly, releasing the growth factor over weeks to months. This double-barrier approach significantly reduces burst release and allows for independent tuning of carrier and hydrogel properties. For instance, dual-release systems that deliver BMP-2 from microspheres and TGF-β3 from the bulk hydrogel have been shown to enhance osteochondral defect repair in animal models.

Chemical Conjugation and Affinity Binding

By covalently linking the growth factor to the hydrogel backbone (or to a carrier peptide), release becomes dependent on the cleavage of that bond, either by hydrolysis or enzymatic action. This method provides the most precise control over release kinetics and can achieve near-zero-order release. However, it requires careful chemistry to avoid denaturing the growth factor or blocking its active site. Affinity-based systems use non-covalent interactions—such as heparin binding, binding to specific ECM components (e.g., aggrecan), or interactions with designed peptide sequences—to retard release. Heparin-mimetic hydrogels that bind growth factors with strong ionic interactions have been particularly successful for sustained delivery of TGF-β and BMP-2.

Stimuli-Responsive Release

Recent advances have introduced "smart" hydrogels that release growth factors in response to specific environmental cues. These include temperature (e.g., PNIPAM), pH (e.g., chitosan/polyacrylic acid composites), enzymes (e.g., MMP-sensitive linkers), or even mechanical loading (e.g., force-induced release). In cartilage repair, an ideal system might release more growth factor during periods of inflammation (low pH, high protease activity) or in response to weight-bearing, thus mimicking the natural dynamic environment of the joint.

Challenges Hindering Clinical Translation

Despite promising preclinical results, only a handful of hydrogel-based growth factor delivery systems have reached clinical testing for cartilage repair. Several hurdles remain:

  • Burst Release: Many hydrogels still exhibit an initial burst of growth factor, which can lead to adverse effects such as ectopic bone formation (with BMP-2) or synovial inflammation. Achieving truly zero-order release over months remains difficult.
  • Immunogenicity and Foreign Body Response: Even "biocompatible" hydrogels can trigger a mild inflammatory response that accelerates degradation and compromises growth factor retention. Synthetic hydrogels often require careful chemical modification to avoid activating immune cells.
  • Mechanical Properties: Hydrogels that are optimized for release often have low stiffness and may not withstand the high compressive and shear forces in the knee joint. Mechanically robust hydrogels, on the other hand, can limit diffusion and cell infiltration. Developing hydrogels that balance mechanical strength with release performance is a key challenge.
  • Growth Factor Stability: Encapsulation in a polymer network does not guarantee protein stability. Many growth factors are prone to aggregation, deamidation, or oxidation during storage and after implantation. Formulation excipients (e.g., sugars, surfactants) are often needed.
  • Manufacturing and Sterilization: Reproducibility in crosslinking density and growth factor loading is difficult to achieve at clinical scale. Sterilization methods such as gamma irradiation or ethylene oxide can degrade both the hydrogel and the protein cargo.
  • Integration with Native Tissue: Even if the growth factor regenerates cartilage, the new tissue must be mechanically integrated with the surrounding native cartilage and subchondral bone. Poor integration leads to delamination and failure.

Future Directions and Emerging Approaches

The field is moving rapidly toward more sophisticated hydrogel platforms that address these limitations. Several trends are notable:

Decellularized ECM Hydrogels

Decellularized cartilage ECM (dECM) powders can be solubilized and reconstituted into hydrogels that retain the native biochemical signals. These hydrogels provide a milieu of growth factors, proteoglycans, and collagen that closely mimics the cartilage microenvironment. dECM hydrogels have been shown to enhance chondrogenesis of MSCs without adding exogenous growth factors, simplifying the delivery system.

3D Bioprinting and Personalized Hydrogels

3D bioprinting allows spatial deposition of hydrogels with precisely controlled architecture, enabling the creation of graded scaffolds that mimic the zonal organization of cartilage (superficial, middle, deep zones). Growth factors can be printed in specific patterns to guide cell differentiation and matrix formation. This technology promises patient-specific implants that match the defect geometry (recent review on bioprinting for cartilage).

VEGF and Dual-Growth Factor Strategies

While vascularization is generally undesirable in avascular cartilage, subchondral bone defects require both osteogenesis and chondrogenesis. Dual-release systems delivering VEGF (for bone angiogenesis) alongside a chondrogenic factor (like TGF-β3) have shown success in osteochondral defect models. Hydrogels that release factors in a spatiotemporal sequence—first promoting bone formation, then cartilage formation—are an active area of research.

Exosomes and Growth Factor Mimetics

An alternative to recombinant proteins is the use of exosomes or secretomes from MSCs, which contain a cocktail of growth factors and cytokines. Hydrogels loaded with exosomes can provide a more natural, sustained signaling environment. Small molecule drugs that mimic growth factor signaling (e.g., Kartogenin, which promotes chondrogenesis) are also being incorporated into hydrogels as cheaper, more stable alternatives.

Clinical Trial Updates

Several hydrogel products are in clinical trials. For example, the use of HA-based hydrogels loaded with TGF-β3 (or autologous MSCs) has shown early promise in small trials for focal cartilage defects. Spherigen’s sprifermin (FGF-18) is delivered as an intra-articular injection (not a hydrogel) but demonstrates the potential of sustained growth factor exposure. A hydrogel-based delivery system for BMP-7 is also under investigation. As regulatory pathways become clearer, we can expect more clinical data in the coming years.

Conclusion

Hydrogel-based delivery systems represent a versatile and powerful platform for achieving sustained release of growth factors in cartilage repair. By leveraging the unique properties of hydrogels—biocompatibility, tunability, and the ability to mimic the ECM—researchers have developed systems that can maintain therapeutic levels of chondrogenic proteins for weeks to months, improving outcomes in animal models. Natural, synthetic, and hybrid hydrogels each offer distinct advantages, and strategies such as microencapsulation and affinity binding have refined the control over release kinetics. Challenges related to mechanical strength, burst release, and clinical manufacturing remain, but emerging approaches including 3D bioprinting, dECM hydrogels, and exosome-loaded gels promise to overcome these hurdles. As the field continues to evolve, hydrogel-based growth factor delivery is poised to become a cornerstone of next-generation cartilage regeneration therapies, ultimately offering patients a non-arthroplasty option for joint preservation and pain relief.